FDA Takes Aim at Billionaire's Misleading Cancer Drug Claims

Unpacking the FDA's Warning

On March 25, 2026, the FDA took a decisive step in addressing misleading drug marketing practices by biotech billionaire Dr. Patrick Soon-Shiong. The agency issued a warning regarding claims made about Soon-Shiong's company, ImmunityBio, and its bladder cancer drug, Anktiva. According to the FDA, Soon-Shiong's statements during a podcast and a television advertisement were not just exaggerated but outright misleading, presenting a false impression of the drug's capabilities.

Claims Under Fire

The FDA's warning specifically targeted claims that Anktiva could treat, cure, or even prevent various types of cancer beyond its approved use for a challenging form of bladder cancer. During an episode of "The Sean Spicer Show," Soon-Shiong asserted that Anktiva is "the most important molecule that could cure cancer," a bold statement that the FDA rigorously challenged.

"The FDA has determined that the TV ad and podcast are false or misleading," the letter stated. It highlighted that Anktiva is intended for new uses for which it lacks approval.

Market Repercussions

The immediate aftermath of the warning saw ImmunityBio's stock plummet by over 21%, closing at $7.42. This sharp decline underscores a critical aspect of the biotech sector: investor confidence can swiftly erode when regulatory bodies intervene, particularly following controversial claims made by company executives. The question remains—how will this impact future FDA interactions and the reputation of pharmaceutical marketing?

FDA's Role in Patient Safety

In issuing the warning to ImmunityBio's CEO Richard Adcock, the FDA emphasized its commitment to ensuring that drug promotions depict a balanced view of risks and benefits. They pointed out that the marketing materials in question lacked essential information about Anktiva's potential side effects, which may include urinary tract infections, chills, and pyrexia, leaving patients vulnerable to misguided expectations.

Highlighting the need for accountability, FDA regulations stipulate that any marketing must adhere to a standard of honesty. The regulator's assertion that the drug was misrepresented as a "cancer vaccine" further compounds these concerns. Such terminology, while catchy, does not align with established medical definitions or the drug's approved applications.

The Ethics of Drug Promotion

As I reflect on these developments, I am reminded of the delicate balance between pharmaceutical innovation and ethical marketing. Companies like ImmunityBio are often at the forefront of breakthroughs that have the potential to save lives, yet responsible promotion is equally crucial. The FDA's warning serves as a reminder that the way drugs are marketed must not only align with presentations made to investors but also with the safety and well-being of patients.

A Path Forward

ImmunityBio has stated its intention to "work cooperatively" with the FDA to address the concerns raised. This response is paramount as it entails not merely compliance but also a commitment to revisiting how the drug's marketing aligns with its approved uses. The company now has 15 days to correct the issues flagged by the FDA and to clarify its marketing strategies going forward.

Conclusion

A regulatory environment that prioritizes patient safety is vital as pharmaceutical companies navigate new innovations and treatments. The FDA's warning to ImmunityBio and Dr. Soon-Shiong illuminates the pressing need for honesty in drug marketing, ultimately safeguarding public trust. As stakeholders—including investors, healthcare providers, and patients—grapple with the fallout, it will be interesting to observe how ImmunityBio adapts its approach in the wake of this significant scrutiny.